Clinical Trial Update: Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression [Phase 2]

View source ↗

Summary

Clinical trial update announcing a Phase II study of Disitamab Vedotin in combination with Tislelizumab and Bevacizumab for locally advanced or metastatic non-s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Disitamab Vedotin (disitamab vedotin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Lung Cancer | Phase 2 | Status: RECRUITING